文献速递肝病

代偿期进展性慢性肝病首次失代偿无创预测模型:一项荟萃分析

Noninvasive Prediction Models of First Decompensation in Compensated Advanced Chronic Liver Disease: A Meta-Analysis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2025-10-10

该系统评价与荟萃分析检索至2025年2月,纳入30项研究、47,647例代偿期进展性慢性肝病(cACLD)患者,评估联合无创标志物预测首次失代偿的准确性。随机效应荟萃分析显示,在cACLD中开发并验证的模型预测最佳,SAVE评分汇总C统计量0.87(95%CI 0.82-0.93),ABC评分0.85(95%CI 0.80-0.89)。所有模型验证与校准有限。

要点

  • cACLD专用无创预测模型对首次失代偿的预测优于其他模型。
  • SAVE评分汇总C统计量0.87,ABC评分0.85。
  • 现有模型验证与校准有限,需外部验证和标准化终点。

核心结论

  • cACLD特异性无创预测模型是预测失代偿的最佳选择。
  • 未来研究应聚焦稳健验证、校准及标准化终点的外部验证。

研究设计与样本

  • 系统评价与荟萃分析,检索截至2025年2月的已发表文章,注册号PROSPERO CRD42024608001。
  • 纳入评估联合2个及以上无创标志物构建的预后模型的研究,排除包含非cACLD人群及仅评估单一标志物的研究。
  • 共筛选6540篇文章,纳入30项研究,涉及47,647例cACLD参与者,描述39个预后模型,其中19个适合荟萃分析。
  • 提取汇总数据包括C统计量和/或受试者工作特征曲线下面积及模型校准。

主要发现

  • 随机效应荟萃分析显示,在cACLD中开发并验证的模型预测最佳,SAVE评分汇总C统计量0.87(95%CI 0.82-0.93),ABC评分0.85(95%CI 0.80-0.89)。
  • 所有模型的验证和校准均有限。
  • 使用侵入性诊断cACLD的队列敏感性分析结果异质性最低,所有评估模型I2<50%。

关键数值与推荐

  • SAVE评分汇总C统计量0.87(95%CI 0.82-0.93)。
  • ABC评分汇总C统计量0.85(95%CI 0.80-0.89)。
  • 侵入性诊断cACLD队列的敏感性分析中所有评估模型I2<50%。

临床怎么用

  • 临床可优先考虑在cACLD人群中开发并验证的无创预测模型(如SAVE、ABC评分)评估首次失代偿风险。
  • 应用模型时需注意其验证和校准有限,应结合临床并在适用人群中谨慎解读。

局限性

  • 所有模型的验证和校准有限。
  • 部分模型不适合荟萃分析,仅19个模型纳入随机效应荟萃分析。
  • 研究间存在异质性,仅在侵入性诊断cACLD队列的敏感性分析中异质性较低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: This review aimed to critically appraise available data to determine the accuracy of noninvasive prediction models (noninvasive tests [NITs]) in identifying patients with compensated advanced chronic liver disease (cACLD) who are at increased risk of a first episode of hepatic decompensation. METHODS: This systematic review and meta-analysis was conducted from all published articles until February 2025. Studies were included if they evaluated performance of an NIT, defined as 2 or more individual noninvasive markers that had been combined into a prognostic model. Studies were excluded if analysis was done on a population that included those without cACLD, and studies examining only singular prognostic markers (including baseline liver stiffness in isolation). Summary data were extracted from published reports consisting of the C-statistic and/or area under the receiver-operating characteristic curve and model calibration. This review was registered with PROSPERO (CRD42024608001). RESULTS: Of 6540 screened articles, 30 were included, consisting of 47,647 participants with cACLD. The articles described 39 prognostic models, of which 19 were suitable for meta-analysis. Random effects meta-analysis found models specifically developed and validated in cACLD provide the best prediction, including the SAVE score (summary C-statistic = 0.87; 95% confidence interval, 0.82-0.93) and ABC score (summary C-statistic = 0.85; 95% confidence interval, 0.80-0.89). There was limited validation and calibration of all models. Sensitivity analysis of cohorts using an invasive diagnosis for cACLD provided the least heterogeneous outcomes, with all assessed models having an I2 <50%. CONCLUSIONS: cACLD-specific NITs offer the best option in predicting decompensation, and future studies should focus on robust validation, calibration, and external validation with standardized endpoints to ensure that models are reliable for guiding clinical practice in applicable populations.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Jeffrey AW, Chen J, Chin A, et al. Noninvasive Prediction Models of First Decompensation in Compensated Advanced Chronic Liver Disease: A Meta-Analysis. Clin Gastroenterol Hepatol. 2025. PMID: 41076042. doi:10.1016/j.cgh.2025.10.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。